Liquidation Opportunity Forward Pharma A/S completed a solvent liquidation in 2025 after a significant exit from DMF-related IP with Biogen. This creates a potential sale of remaining IP, licenses, or related know-how to entities seeking to assume or monetize DMF assets or explore royalty-style arrangements.

Licensing Footprint Biogen holds an irrevocable license to Forward Pharma’s IP, with a history of a substantial upfront cash inflow. This suggests a potential opportunity to engage downstream licensees, strategic buyers, or investors interested in DMF formulations or inflammatory and neurological indication platforms.

Small Team, Niche IP With a lean team and a closed business footprint, the company may have residual value in its proprietary formulation and related IP portfolio. This could appeal to niche biotech aggregators, patent monetization firms, or partners seeking specialized DMF-related assets without ongoing R&D overhead.

Strategic Partnerships Past collaboration with Ixchel Pharma on Friedreich's ataxia signals openness to RS& D partnerships or asset deals. A sales approach could target contract research organizations, co-development partners, or biopharma companies seeking to expand into neurology and inflammatory indications via proven DMF assets.

Market Signals Historical Phase III psoriasis initiatives and ongoing interest in DMF assets indicate continuing market relevance of DMF-based therapies. Outreach to companies pursuing dermatology, neurology, or metabolism indications may uncover demand for licenses, divestitures, or collaboration on remaining assets related to FP187 or DMF formulations.